In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Start-Up Previews (04/2008)

Executive Summary

A preview of the emerging health care companies profiled in the current issue of Start-Up. This month's profile group, "Nanotechnology, a Balm for the Challenges of Drug Delivery," features profiles of BIND Biosciences, Liquidia Technologies, Nanolymf, Tempo Pharmaceuticals, and TransGenex Nanobiotech. Plus these Start-Ups Across Health Care: Breathe Technologies, Crospon, and InterMed Discovery.

You may also be interested in...



Breathe Technologies Inc.

The developers of a miniature, wearable ventilator for people with severe respiratory disorders view their product as the iPod of ventilators. Breathe Technologies aims to commercialize the first truly ambulatory ventilator. The company believes its innovative technology will fill an unmet need for patients with severe ventilatory insufficiency, both in the hospital setting and in the home.

Crospon Ltd.

New imaging technology employed through a therapeutic endoscope provides the most relevant information to diagnose gastroesophageal reflux disease (GERD), according to its manufacturer, Crospon. Furthermore, the Irish start-up says its novel EndoFLIP (endoscopic functional lumen imaging probe) technology can be used to assist in GERD surgeries and to assess the results.

TransGenex Nanobiotech Inc.

TransGenex Nanobiotech is taking a multi-pronged approach to building a nanotechnology company. In the short term, the company is generating revenue from sales of its custom nanoparticles and its Nanogene reagents that can be used to deliver genes to cells. It is also using its technology to develop diagnostic platforms, especially for lung and ovarian cancer. Finally, TransGenex plans to develop its own novel drug candidates. It's focusing first on products with anti-inflammatory properties, which could find application in asthma as well as several cancers.

Related Content

Related Companies

UsernamePublicRestriction

Register

SC027449

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel